VIA EDGAR
February 11, 2019
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Mr. Jeffrey Gabor
| Re: | Catalyst Biosciences, Inc. |
| Registration Statement on Form S-3 |
| File No. 333- 228970 |
| Request for Acceleration of Effectiveness |
Dear Mr. Gabor:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Catalyst Biosciences, Inc., a Delaware corporation (the “Company”), hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement to become effective at 4:00 PM Eastern Time on February 14, 2019, or as soon thereafter as practicable.
Please contact Stephen B. Thau of Morrison & Foerster LLP, counsel to the Company, at (650) 813-5640 should you have any questions or require additional information regarding this request and to notify us that the Registration Statement has been declared effective pursuant to this acceleration request.
| Very truly yours, | ||
| CATALYST BIOSCIENCES, INC. | ||
| By: | /s/ Fletcher Payne | |
| Name: | Fletcher Payne | |
| Title: | Chief Financial Officer | |
| cc: | Stephen B. Thau, Morrison & Foerster LLP |